

3D DIAGNOSTIC IMAGING PLC
(“3D ” or “the Company”)
(PLUS Ticker 3DDP)

£750,000 raised by way of a successful placing of new shares with existing investors

3D, whose subsidiary CarieScan is a producer of handheld devices for the early detection and monitoring of tooth decay, today announces that it has raised a total of £750,000 from existing investors by way of a placing of 9,375,000 new Ordinary Shares of 0.1p each at a subscription price of 8 pence per share, which price represents a premium of approximately 14% over the market price at the close of business on 17 November 2009 (the “Placing”).

The Directors intend that the net proceeds from the Placing will be applied to cover the costs of producing stock for resale, to fund ongoing design development of the PRO sensors, for marketing support and for general working capital purposes. The PRO has already been CE marked for distribution in Europe and is currently undergoing the FDA 510k approval process for distribution in the United States. This month the company made its first sales of the PRO.

Dealings in the new Ordinary Shares are expected to commence at 8am on 18 November 2009. Following the Placing the Company has a total of 107,304,285 ordinary shares in issue and its principal shareholders are as follows.

Shareholder:	Shares held	% of issued
Evolve Capital plc	44,529,911	41.50
Scottish Enterprise	31,613,393	29.46
Peter Hoskins	7,437,053	6.93
Jemima Hoskins	6,875,714	6.41
James Noble	6,244,871	5.82
Graham Lay	5,596,629	5.22
Marley Properties Ltd	3,434,000	3.20
Others	1,572,714	1.46
Total	107,304,285	100

This announcement should be read in conjunction with the preliminary results announcement for the year 30 June 2009, which is also issued today.

Commenting on the fundraising, Graham Lay, CEO, said:

“I am delighted that our existing investors have supported the fundraising. The business has achieved a number of milestones this year and we are now at a point where we can really push for the wide-scale adoption of the CarieScan PRO by dentists in the UK and overseas. There is

already significant interest from them and the proceeds from the fundraising will enable us to convert this interest into sales.”

The directors accept responsibility for the content of this announcement.

Enquiries:

3D Diagnostic Imaging Plc +44 (0) 138 256 0910
Graham Lay, CEO

St Helens Capital Partners LLP +44 (0) 20 7368 6959
Oliver Cooke
Mark Anwyl

Buchanan Communications +44 (0) 207 466 5000
Diane Stewart
Jennie Spivey
Carrie Clement